08:45 AM EDT, 07/08/2024 (MT Newswires) -- NewAmsterdam Pharma ( NAMS ) said Monday it has completed patient enrollment for a phase 3 clinical trial evaluating the use of obicetrapib in combination with ezetimibe in adult patients with heterozygous familial hypercholesterolemia and/or either with or at risk of developing atherosclerotic cardiovascular disease.

The 407 qualifying patients' low-density lipoproteins also are not adequately controlled despite being on maximally tolerated lipid-modifying therapies.

Chief Executive Michael Davidson said the enrollment completion advances obicetrapib through late-stage clinical development and "brings us closer to delivering a simple and convenient once-daily tablet to the millions of people suffering from dyslipidemia."